Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -165.56% is 41% below its 5-year average of -117.61%, around the middle of its 5-year range (-340.73%–-42.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 27.89% above its 12-month average of -229.60%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -165.56%.
RETURN ON INVESTED CAPITAL (ROIC)
-165.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-229.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-167.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-117.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+27.89%
CURRENT VS 3Y AVG
+1.26%
CURRENT VS 5Y AVG
-40.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-364.47%
vs the sector median at left
Cardiol Therapeutics Inc.
Market Cap
$151.58M
Return on Invested Capital (ROIC)
-165.56%
TTM Avg
-229.60%
3Y Avg
-167.68%
5Y Avg
-117.61%
Market Cap
$153.44M
Return on Invested Capital (ROIC)
-22.15%
TTM Avg
-29.24%
3Y Avg
-31.64%
5Y Avg
-30.48%
Market Cap
$151.28M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.34M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-138.87%
3Y Avg
-97.17%
5Y Avg
-81.85%
Market Cap
$146.82M
Return on Invested Capital (ROIC)
-64.72%
TTM Avg
-41.34%
3Y Avg
-24.79%
5Y Avg
-23.17%
Market Cap
$146.82M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$147.35M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$146.26M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
Market Cap
$156.63M
Return on Invested Capital (ROIC)
-13.94%
TTM Avg
-16.11%
3Y Avg
-25.11%
5Y Avg
-17.04%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $151.58M | -165.56% | -229.60% | -167.68% | -117.61% |
| Neuronetics, Inc. (STIM)vs › | $153.44M | -22.15% | -29.24% | -31.64% | -30.48% |
| Veraxa Biotech Holding AG (VRXA)vs › | $151.28M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $154.34M | N/A | -138.87% | -97.17% | -81.85% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $146.82M | -64.72% | -41.34% | -24.79% | -23.17% |
| Codexis, Inc. (CDXS)vs › | $146.82M | -23.41% | -38.99% | -40.72% | -30.95% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $147.35M | -56.53% | -185.89% | -125.01% | -88.85% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.26M | -118.67% | -87.91% | -55.09% | -41.64% |
| Inogen, Inc. (INGN)vs › | $156.63M | -13.94% | -16.11% | -25.11% | -17.04% |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.96M | -27.25% | -49.08% | -43.31% | -52.54% |
ROIC
-165.6%
ROE
-155.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -165.56% |
| 2026-03-31 | -147.38% |
| 2025-12-31 | -188.45% |
| 2025-09-30 | -340.73% |
| 2025-06-30 | -305.88% |
| 2025-03-31 | -205.41% |
| 2024-12-31 | -148.38% |
| 2024-09-30 | -324.96% |
| 2024-06-30 | -168.20% |
| 2024-03-31 | -123.97% |
| 2023-12-31 | -77.31% |
| 2023-09-30 | -89.24% |
| 2023-06-30 | -67.40% |
| 2023-03-31 | -86.91% |
| 2022-12-31 | -83.21% |
| 2022-09-30 | -63.42% |
| 2022-06-30 | -53.89% |
| 2022-03-31 | -46.84% |
| 2021-12-31 | -42.04% |
| 2021-09-30 | -100.52% |
| 2021-06-30 | -70.67% |
| 2021-03-31 | -109.85% |
| 2020-12-31 | -113.15% |
| 2020-09-30 | -46.64% |
| 2020-06-30 | -41.86% |
| 2020-03-31 | -99.00% |
| 2019-12-31 | -87.14% |
| 2019-09-30 | -81.52% |
| 2019-06-30 | -63.27% |
| 2019-03-31 | -47.06% |
| 2018-12-31 | -33.80% |
| 2018-09-30 | -50.40% |
| 2018-06-30 | -26.56% |
| 2018-03-31 | -71.32% |
